RA
FATE icon

Royce & Associates’s Fate Therapeutics FATE Stock Holding History

Royce & Associates’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-43,399
Closed -$319K – 893
2024
Q1 		$319K Sell
43,399
-63,919
-60% -$396K ﹤0.01% 815
2023
Q4 		$401K Buy
107,318
+76,979
+254% +$182K ﹤0.01% 804
2023
Q3 		$64.3K Buy
+30,339
New +$101K ﹤0.01% 903

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Royce & Associates's FATE Position: Q2 2024 in Review

Royce & Associates sold out of Fate Therapeutics (FATE) in Q2 2024, closing a stake of 43,399 shares — an estimated $319K sold.

Royce & Associates first reported a position in FATE in Q3 2023 and held it in 3 quarters. The position peaked at $401K in Q4 2023. 182 funds tracked by Wall St. Rank hold FATE as of Q2 2024.

  • Royce & Associates reported no remaining Fate Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Royce & Associates sold 43,399 Fate Therapeutics shares in Q2 2024, an estimated $319K.
  • Royce & Associates first reported a position in Fate Therapeutics in Q3 2023 and held it in 3 quarters.
  • Royce & Associates's Fate Therapeutics position peaked at $401K in Q4 2023.
  • 182 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2024.

Based on Royce & Associates's 13F filing for Q2 2024, filed 13 Aug 2024.